VIRAL TREATMENT

Abstract: A pharmaceutical composition that inhibits or slows the infection or reinfection of animals, particularly mammals, by HIV or other retroviruses is disclosed. The composition comprises from about 10 mg to about 6000 mg of a (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadiazol)-3-yl urea derivative of formula: (I), wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 1-4, R1 is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula -O(CH2)YCH3 wherein y is from 1 to 6, or a pharmaceutically acceptable acid addition salt or prodrug thereof. The preferred compound is (5-phenyl-1,2,4-thiadazol-3-yl) thiourea.

Description: VIRAL TREATMENT This application is a continuation in part of application of J. B Camden, serial number 09/ — -- filed March 31, 1999. TECHNICAL FIELD This invention is a pharmaceutical composition that is effective in preventing HIV and other viral infections. The composition can be used to treat viral infections, notably hepatitis, including hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency syndrome (HIV), and Kaposi sarcoma. The composition compπses one or more (5-aryl-l,2,4-thiadιazol)-3-yl urea or (5-aryl-l,2,4-thiadιazol)-3-yl thiourea derivatives. The method of preventing viral infections is also disclosed BACKGROUND OF THE INVENTION HIV and other viral infections such as hepatitis are a few of the leading causes of death. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans HIV is a disease in which a virus is replicated m the body or m host cells. The virus attacks the body's immune system Several drugs have been approved for treatment of this devastating disease, including azidovudme (AZT), didanosme (dideoxymosme, ddl), d4T, zalcitabme (dideoxycytosme, ddC), nevirapme, lamivudme (epivir, 3TC), saqumavir (Invirase), πtonavir (Norvir), mdmavir (Cπxivan), and delavirdme (Rescπptor). See M. I. Johnston & D. F. Hoth, Science, 260(5112), 1286-1293 (1993) and D. D. Richman, Science, 272(5270), 1886-1888 (1996). An AIDS vaccine (Salk's vaccine) has been tested and several proteins which are chemokmes from CD8 have been discovered to act as HIV suppressers. In addition to the above synthetic nucleoside analogs, proteins, and antibodies, several plants and substances deπved from plants have been found to have m vitro anti-HIV activity. However, HIV virus is not easily destroyed nor is there a good mechanism for keeping the host cells from replicating the virus. Thus, medical professionals continue to search for drugs that can prevent HIV and retroviral infections, treat HIV carriers to prevent their disease from progressing to full-blown deadly AIDS, and to treat the AIDS patient. Herpes simplex virus (HSV) types 1 and 2 are persistent viruses that commonly infect humans; they cause a variety of troubling human diseases. HSV type 1 causes oral "fever blisters" (recurrent herpes labiahs). and HSV type 2 causes genital herpes, which has become a major venereal disease in many parts of the world. No fully satisfactory treatment for genital herpes currently exists. In addition, although it is uncommon, HSV can also cause encephalitis, a life-threatening infection of the brain. (The Merck Manual, Holvey, Ed., 1972; Whitley, Herpes Simplex Viruses, In: Virology, 2nd Ed., Raven Press (1990)). A most serious HSV-caused disorder is dendritic keratitis, an eye infection that produces a branched lesion of the cornea, which can in turn lead to permanent scarring and loss of vision. Ocular infections with HSV are a major cause of blindness. HSV is also a virus which is difficult, if not impossible to cure. Hepatitis is a disease of the human liver. It is manifested with inflammation of the liver and is usually caused by viral infections and sometimes from toxic agents. Hepatitis may progress to liver cirrhosis, liver cancer, and eventually death. Several viruses such as hepatitis A, B, C, D, E and G are known to cause various types of viral hepatitis Among them, HBV and HCV are the most serious. HBV is a DNA virus with aviπon size of 42 nm. HCV is a RNA virus with a viπon size of 30-60 nm. See D. S. Chen, J. Formos. Med. Assoc. 95(1), 6-12 (1996) Hepatitis C infects 4 to 5 times the number of people infected with HIV. Hepatitis C is difficult to treat and it is estimated that there are 500 million people infected with it worldwide (about 15 times those infected with HIV). No effective immunization is currently available, and hepatitis C can only be controlled by other preventive measures such as improvement m hygiene and sanitary conditions and interrupting the route of transmission At present, the only acceptable treatment for chronic hepatitis C is mterferon which requires at least six (6) months of treatment and or ribavarin which can inhibit viral replication in infected cells and also improve liver function in some people. Treatment with mterferon however has limited long term efficacy with a response rate about 25%. Hepatitis B virus infection can lead to a wide spectrum of liver injury. Moreover, chronic hepatitis B infection has been linked to the subsequent development of hepatocellular carcinoma, a major cause of death. Current prevention of HBV infection is a hepatitis B vaccination which is safe and effective. However, vaccination is not effective in treating those already infected (i.e., carriers and patients). Many drugs have been used in treating chronic hepatitis B and none have been proven to be effective, except mterferon. Treatment of HCV and HBV with mterferon has limited success and has frequently been associated with adverse side effects such as fatigue, fever, chills, headache, myalgias, arthralgias, mild alopecia, psychiatric effects and associated disorders, autoimmune phenomena and associated disorders and thyroid dysfunction. Because the mterferon therapy has limited efficacy and frequent adverse effects, a more effective regimen is needed. In the present invention it has been discovered that the compounds described above are useful for the treatment of hepatitis C virus, hepatitis B virus, heφes simplex and the treatment of HIV infection and other viral infections. SUMMARY OF THE INVENTION A method of preventing HIV and other viral infections comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a member selected from the group consisting of (5-aryl- 1,2,4- fhiadiazol)-3-yl thiourea derivative or (5-aryl- l,2,4-thiadiazol)-3-yl urea derivative having the formula: wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 0-4, R, is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula - O(CH 2 ) y CH 3 wherein y is from 0 to 6 or a pharmaceutical addition salt or prodrug thereof is disclosed. Preferred the anti-viral preventive compositions comprise a therapeutically effective amount of an compound having the formula: The present invention provides a method for preventing HIV infection in a patient in need thereof comprising administering a pharmaceutically or therapeutically effective or acceptable amount of the composition as described above The present invention also comprises the use of a combination therapy in the prevention of viral infections, in particular m the prevention of HIV. The compositions can be used m conjunction with other treatments. The route of administration is the same as for other medical treatments. The drug can be given daily or from 1 to 4 times a week. DETAILED DESCRIPTION OF THE INVENTION A. DEFINITIONS As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used m the manner of this invention. As used herein, the term "therapeutically effective amount" is meant an amount of a compound of the present invention effective to yield the desired therapeutic response. For example to inhibit HIV infection or treat the symptoms of infection m a host or an amount effective to treat hepatitis. The specific therapeutically effective amount will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal or animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. As used herein, a "pharmaceutical addition salt" is a salt of the arylthiazolyl thiourea or urea which are modified by making an acid or base salt of the compounds. Examples of pharmaceutical addition salts include, but are not limited to, mineral or organic acid salt of basic residues such as amines, alkali or organic salt of acidic residues such as carboxylic acids Preferably the salts are made using an organic or inorganic acid These preferred acid addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, sahcylates, ascorbates, and the like. As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-viral agent to the animal or human. The carrier can be liquid or solid and is selected with the planned manner of administration in mind. As used herein, the terms "anti-viral compounds" are the (5-aryl-l,2,4-thιadιazol)-3-yl thiourea derivatives or (5-aryl-l,2,4-thιadιazol)-3-yl urea derivative and the pharmaceutical addition salts or prodrugs thereof. The preferred anti-viral compound is 5-phenyl-3-thιoureιdo- 1,2,4-thιadιazole. As used herein, the term "(5-aryl- l,2,4-thιadιazol)-3-yl thiourea derivatives or "(5-aryl- l,2,4-thιadιazol)-3-yl urea derivatives" or "aryl thiadiazolyl thiourea or urea derivatives" includes compounds having the formula- H wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 0-4, R, is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula -0(CH 2 ) y CH 3 wherein y is from 1 to 6 or its pharmaceutical addition salt or its prodrug. As used herein, "Alkyl" can be any branched, straight chain or cyclic alkane or alkene generally having less than 8 carbons As used herein "Aryl" is any substituted phenyl compound and including phenyl itself wherein R is hydrogen and n is 5. As used herein, the term "Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug according to the formula of derivatives described above in vivo when such prodrug is administered to a mammalian subject or patient m need of treatment. Prodrugs of the arylthiadiazolyl thiourea or urea derivatives are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either m routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein free hydroxyl, sulfhydryl, or amine groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, ammo, or sulfhydryl group, respectively Examples of prodrugs include, but are not limited to, acetate, formate, or benzoate derivatives of alcohol and amine functional groups in the arylthiazolyl thiourea derivatives or arylthiazoloyl urea derivative; phosphate esters, dimethylglycme esters, ammoalkylbenzyl esters, ammoalkyl esters and carboxyalkyl esters of alcohol and phenol functional groups or the , ammoalkylbenzyl amides, ammoalkyl amides and carboxyalkyl amides of the ammo functional groups in the arylthiazolyl thiourea derivatives or arylthiazoloyl urea derivative; and the like. As used herein "viruses" includes viruses which infect animals or mammals, including humans. Viruses includes HIV, influenza, polio viruses, heφes simplex, hepatitis B, hepatitis C and other viral strains of hepatitis, Kaposi's sarcoma, rhmoviruses, and the like. As used herein "combination therapy" means that the patient in need of the drug is treated or given another drug for the disease m conjunction with the arylthiazolyl thiourea or arylthiazolyl urea derivatives. This combination therapy can be sequential therapy where the patient is treated first with one or more drugs and then the other, or two or more drugs are given simultaneously. B. THE ANTI- VIRAL COMPOUNDS The anti-viral material is (5-aryl-l,2,4-thιadιazol)-3-yl thiourea derivative or (5-aryl- l,2,4-thιadιazol)-3-yl urea derivative or their pharmaceutical addition salt or prodrugs having the formula: wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 0-4, R, is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula -0(CH 2 ) v CH 3 wherein y is from 0 to 6, preferably from 2 to 4. Preferably the (5-aryl-l,2,4-thιadιazol)-3-yl- urea or (5-aryl- l,2,4-thιadιazol)-3-yl- thiourea derivative is substituted with an alkyl of less than 4 carbons, a halogen, preferably a chloro in the 7 or 8 position and the remaining substituents of the benzene πng are hydrogen. The most preferred anti-viral is (5-phenyl-l,2,4-thιadιazol)-3-yl thiourea. Pharmaceutical addition salt of the arylthiazolyl thiourea or arylthiazolyl urea derivatives include the conventional non-toxic salt or the quaternary ammonium salt of the arylthiazolyl thiourea or arylthiazolyl urea deπvatives formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuπc, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succmic, glycohc, stearic, lactic, malic, tartaπc, citric, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfamlic, 2-acetoxybenzoιc, fumaric, toluenesulfomc, methanesulfonic, ethane disulfonic, oxalic, lsethiomc, and the like. C. SYNTHESIS The arylthiazolyl thiourea or arylthiazolyl urea derivatives can be prepared in a number of ways well known to one skilled m the art of organic synthesis. The arylthiazolyl thiourea or arylthiazolyl urea derivatives can be synthesized using the methods described below, together with synthetic methods known m the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Each of the references cited below are hereby mcoφorated herein by reference. The compounds can be synthesized by a desulphuπzation of aromatic thioureas or urea compounds using hydrogen peroxide in alkali or by reacting the corresponding 3-amιno-5-aryl- 1,2,4-thιadιazole with ethoxy carbonyl isothiocyanate to produce the ethoxycarbonyl-3-(5'-aryl- ,2',4-thιadιazol-3'-yl)thιourea or 3-(5'-aryl-r,2',4-thιadιazol-3'-yl) urea which is then reacted with sodium hydroxide in ethanol and then acidified. (5-Phenyl-l,2,4-thιadιzol)-3-yl thiourea is prepared by the method described in Kurzer, et al, J. Chem. Soc. Perkin Trans. 1(2), 311-314 (1985) and Kurzer, et al. J. Heterocvcl. Chem.. 26 (2), 355-60 (1989). (5-Phenyl-l,2,4-thιadιzol)-3-yl thiourea can also be prepared by the hydrolysis of 3-[N- benzoylthιoureιdo]-5-phenyl-l,2,4-thιadιazole using 3 molar potassium hydroxide at about 60°C. The mixture is cooled, and then acidified with concentrated hydrochloric acid. Concentrated ammonium hydroxide is then used to basify the resultant product The material from this hydrolysis procedure is pure (about 99%) and the yield is high. The pharmaceutical addition salt of the present invention can be synthesized from the arylthiazolyl thiourea or arylthiazolyl urea derivatives which contain a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometπc amount of the appropπate base or acid in water or in an organic solvent, or m a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitπle are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, the disclosure of which is hereby incoφorated by reference. The disclosures of all of the references cited herein are hereby incoφorated herein by reference in their entirety. D. DOSAGE The compounds can be administered m one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill m the art. The compounds can be administered in one dose, continuously or intermittently throughout the course of treatment. The compounds may also be given daily or from 1 to 4 times a week. The compounds of the present invention can be given m one or more doses on a daily basis or from one to three times a week. Twice weekly dosing over a period of at least several weeks is preferred. Often the anti-viral compounds will be administered for extended periods of time and may be administered for the lifetime of the patient. Methods of determining the most effective means and dosage of administration are well known to those of skill m the art. Single or multiple administrations can be carried out with one dose level and pattern being selected by the administrator. The compounds are generally safe The oral LD 50 is greater than 6000 mg/kg in mice and there are no special handling requirements. By way of general guidance, a dosage of as little as about 1 milligrams (mg) per kilogram (kg) of body weight and preferably as little as 10 mg/kg and up to about 10,000 mg per kg of body weight is suitable. Preferably from 10 mg/kg to about 5000 mg/kg of body weight is used. Most preferably the doses are between 250 mg/kg to about 5000 mg/kg. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. By way of guidance the human dose is about 1/12 that of mice. Thus, if 25 mg/kg is effective in mice, a dose of 2 mg/kg would be used for a 60 kg person, and a typical dosage would be 120 mg. The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and/or weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. E. METHOD OF ADMINISTERING AND DOSAGE DELIVERY FORMS The compounds of the present invention can be administered by any suitable means including, but not limited to, for example, oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublmgual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal), mtravesical or injection into or around the virus. The dosage amounts are based on the effective inhibitory concentrations observed in antiviral studies. The preferred route will vary with the (1) condition and age of the recipient, (2) virus and being treated (3) nature of the infection and (4) desired blood levels. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of the compounds of the present invention formulated with an appropriate carrier, other antiviral agents or compounds or diluents to facilitate application will be the preferred method of admimsteπng the compounds to warm blooded animals The (5-aryl- l,2,4-thιadιzol)-3-yl thiourea derivatives or (5-aryl-l,2,4-thιadιzol)-3-yl urea derivatives are preferably micromzed or powdered so that it is more easily dispersed and solubihzed by the body. Processes for grinding or pulverizing drugs are well known m the art. For example, a hammer mill or similar milling device can be used. The preferred particle size is less than about lOOμ and preferably less than 50μ. These compounds are not very soluble, and therefore are preferably given in tablet form or as a suspension. Suitable methods of administering the compounds of the present invention and dosage forms can be found herein below. The (5-aryl- l,2,4-thιadιzol)-3-yl thiourea derivatives or (5-aryl- l,2,4-thιadιzol)-3-yl urea derivatives of this invention can be administered as treatment for viral infections by any means that produces contact of the active agent with the agent's site of action m the body. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or m a combination of therapeutic. Preferably the compounds of the present invention are administered as a pharmaceutical formulation comprising at least one compound of the present invention, as defined above, together with one or more pharmaceutically acceptable carriers. It can be co-admmistered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form or as a liposome The compounds of the present invention may also be administered in the form of liposome delivery systems, such as small umlamellar vesicles, large unilamallar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamme, or phosphatidylcholmes. The (5-aryl-l,2,4-thιadιzol)-3-yl thiourea derivatives or (5-aryl-l,2,4-thιadιzol)-3-yl urea derivatives of the present invention can also be coupled with soluble polymers as targetable drug earners Such polymers can include polyvmylpyrrohdone, pyran copolymer, polyhydroxylpropylmethacrylamide-phenol, polyhy droxyethylaspartamidephenol , or polyethyleneoxide-polylysme substituted with palmitoyl residues. Furthermore, the compounds of the present invention can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslmked or amphipathic block copolymers of hydrogels. 1. Combination Therapy The compounds of the present invention may additionally be combined with other antiviral compounds to provide an operative combination It is intended to include any chemically compatible combination of a compound of this inventive group with other compounds of the inventive group or other compounds outside of the inventive group, as long as the combination does not eliminate the antiviral activity of the compound of this inventive group For example, one or more (5-aryl-l,2,4-thιadιazol)-3-yl thiourea derivatives or (5-aryl- 1,2,4- thιadιzol)-3-yl urea derivatives can be combined with other antiviral agents or potentiators. Potentiators are materials which affect the body's response to the anti-viral agent. In the case of HIV a combination therapy with AZT, TC-3 or protease inhibitors is effective In the case of hepatitis, cyclovir, famciclovir or valacyclovir, Ribaviπn, mterferon or combinations of Ribaviπn and Interferon or beta globulin is administered as a combination therapy For heφes, a recombinant alpha mterferon can be used as a combination therapy. In some embodiments of the invention, a (5-aryl-l,2,4-thιadιazol)-3-yl thiourea derivatives or (5-aryl- l,2,4-thιadιzol)-3-yl urea derivatives is used m combination with one or more other therapeutic agents, such as anti-mflammatory, anti-viral, anti-fungal, amoebicidal, tnchomonocidal, analgesic, anti-neoplastic, anti-hypertensives, anti-microbial and/or steroid drugs, to treat antiviral infections. In some preferred embodiments, viral infections are treated with a combination of one or more (5-aryl- l,2,4-thιadιazol)-3-yl thiourea derivatives or (5-aryl- l,2,4-thιadιzol)-3-yl urea derivatives with one or more of beta-lactam antibiotics, tetracyclmes, chloramphemcol, neomycm, gramicidin, bacitracin, sulfonamides, nitrofurazone, nalidixic acid, cortisone, hydrocortisone, betamethasone, dexamethasone, fluocortolone, predmsolone, tπamcmolone, mdomethacm, sulmdac, acyclovir, amantadine, πmantadine, recombinant soluble CD4 (rsCD4), anti-receptor antibodies (for rhmoviruses), nevirapme, cidofovir (Vistide™), tπsodium phosphonoformate (Foscarnet™), famcyclovir, pencyclovir, valacyclovir, nucleic acid/replication inhibitors, mterferon, zidovudme (AZT, Retrovir™), didanosine (dideoxymosme, ddl, Videx™), stavudme (d4T, Zeπt™), zalcitabine (dideoxycytosme, ddC, Hivid™), nevirapme (Viramune™), lamivudine (Epivir™, 3TC), protease inhibitors, saqumavir (Invirase™, Fortovase™), πtonavir (Norvir™), nelfinavir (Viracept™), efavirenz (Sustiva™), abacavir (Ziagen™), amprenavir (Agenerase™) lndmavir (Cπxivan™), ganciclovir, AzDU, delavirdme (Rescπptor™), πfampin, clathiromycm, erythropoietm, colony stimulating factors (G-CSF and GM-CSF), non-nucleoside reverse transcπptase inhibitors, nucleoside inhibitors, adπamycm, fluorouracil, methotrexate, asparagmase and combinations thereof A "potentiator" can be any material which improves or increase the efficacy of the pharmaceutical composition or acts as an lmmunomodulator. One such potentiator is tπprolidme and its cis-isomer which is used in combination with more (5-aryl- l,2,4-thιadιazol)-3-yl thiourea derivatives or (5-aryl-l,2,4-thιadιzol)-3-yl urea derivatives and optionally another therapeutic agent and or anti-viral agent. Tπprohdine is described in US 5,114,951 (1992). Another potentiator is procodazole, lH-benzιmιdazole-2-propanoιc acid; [β-(2-benzιmιdazole) propionic acid; 2-(2-carboxyethyl)benzιmιdazole; propazol]. Procodazole is a non-specific lmmunoprotective agent against viral and bacterial infections used with the compositions claimed herein. It is effective with one or more (5-aryl- l,2,4-thιadιazol)-3-yl thiourea derivatives or (5- aryl-l,2,4-thιadιzol)-3-yl urea derivatives in treating viral infections and can be combined with one or more other therapeutic agents. The combination therapy can be sequential, that is the treatment with one agent first and then the second agent, or it can be treatment with both agents at the same time. The sequential therapy can be withm a reasonable time after the completion of the first therapy before beginning the second therapy. The treatment with both agents at the same time can be in the same daily dose or in separate doses. For example treatment with one agent on day 1 and the other on day 2. The exact regimen will depend on the disease being treated, the seventy of the infection and the response to the treatment. 2. Unit dosage The compounds of the present invention may administered in a unit dosage fonn and may be prepared by any methods well known in the art. Such methods include combining the compounds of the present invention with a earner or diluent which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly mixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. A pharmaceutical carrier is selected on the basis of the chosen route of administration and standard pharmaceutical practice. Each carrier must be "acceptable" In the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used. Examples of suitable solid carriers include lactose, sucrose, gelatin, agar and bulk powders. Examples of suitable liquid carriers include water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions, and solution and or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid carriers may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents Preferred carriers are edible oils, for example, corn or canola oils Polyethylene glycols, e.g. PEG, are also good carriers. Dosage forms (compositions suitable for administration) comprise from about 1 milligram to about 1000 milligrams of active ingredient per dosage unit. Preferably the dosage forms will contain from about 10 mg to about 500 mg. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0 5 to about 95% by weight based on the total weight of the dosage unit. 3. Pharmaceutical Kits The present invention also includes pharmaceutical kits useful, for example, for the treatment of hepatitis infection, which comprise one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a (5-aryl- 1,2,4- thιadιazol)-3-yl thiourea derivatives or (5-aryl-l,2,4-thιadιzol)-3-yl urea derivatives. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Printed instructions, either as inserts or as labels, indicating quantities of the components to be admmistered, guidelines for administration, and/or guidelines for mixing the components, can also be included m the kit. In the present disclosure it should be understood that the specified materials and conditions are important m practicing the invention but that unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the invention from being realized. Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in US. Pat. No. 3,903,297 to Robert, issued Sept. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are descnbed herein below. Oral formulations suitable for use in the practice of the present invention include capsules, gels, cachets, tablets, effervescent or non-effervescent powders or tablets, powders or granules; as a solution or suspension in aqueous or non-aqueous liquid; or as an oil-m-water liquid emulsion or a water-m-oil emulsion. The compounds of the present invention may also be presented as a bolus, electuary or paste. The formulations for oral administration may comprise a non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, cyclodextnn and cyclodextnn derivatives and the like. Capsule or tablets can be easily formulated and can be made easy to swallow or chew. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. A tablet may be made by compression or molding, optionally with one or more additional ingredients. Compressed tables may be prepared by compressing the active ingredient in a free flowing form (e.g., powder, granules) optionally mixed with a binder (e.g., gelatin, hydroxypropylmethlcellose), lubncant, inert diluent, preservative, dismtegrant (e.g., sodium starch glycolate, cross-linked carboxymethyl cellulose) surface-active or dispersing agent. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium algmate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient. Tablets may also optionally be provided with an enteric coating to provide release in parts of the gut other than the stomach. Formulations suitable for topical administration m the mouth wherein the active ingredient is dissolved or suspended m a suitable earner include lozenges which may comprise the active ingredient m a flavored carrier, usually sucrose and acacia or tragacanth; gelatin, glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient a suitable liquid carrier. Topical applications for administration according to the method of the present invention include ointments, cream, suspensions, lotions, powder, solutions, pastes, gels, spray, aerosol or oil. Alternately, a formulation may comprise a transdermal patch or dressing such as a bandage impregnated with an active ingredient and optionally one or more carriers or diluents. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. The topical formulations may desirably include a compound which enhances absoφtion or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues. The oil phase of the emulsions of the composition used to treat subjects in the present invention may be constituted from known ingredients in a known manner. This phase may comprise one or more emulsifϊers. For example, the oily phase comprises at least one emulsifier with a fat or an oil or with both a fat and an oil or a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. Together, the emulsifier(s) with or without stabilizer(s) make up an emulsifying was, and the wax together with the oil and/or fat make up the emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation include Tween 60, Span 80, cetosteryl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate, paraffin, straight or branched chain, mono-or dibasic alkyl esters, mineral oil. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, the properties required and compatibility with the active ingredient. The compounds may also be administered vaginally for example, as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient. Such carriers are known in the art. Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate. Formulations suitable for nasal administration may be administered in a liquid form, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer, including aqueous or oily solutions of the active ingredient. Formulations for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, of less than about 100 microns, preferably less than about 50 microns, which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials. Extemporaneous injections solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field. Intravenously, the most preferred doses can range from about 1 to about 10 mg/kg/minute during a constant rate infusion. (5-Aryl-l,2,4-thiadizol)-3-yl derivatives or (5-aryl- 1,2,4- thiadizol)-3-yl urea derivatives can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three, or four times daily. The (5-aryl- 1,2,4- thiadizol)-3-yl- derivatives or (5-aryl- l,2,4-thiadizol)-3-yl urea derivatives can be given in one or more doses on a daily basis or from one to three times a week. The present invention additionally include administering compounds of the herein described formula for the use in the form of veterinary formulations, which may be prepared, for example, by methods that are conventional in the art. Useful pharmaceutical dosage forms for administration of the compounds of this invention are illustrated as follows: Capsules A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried. Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalhne cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings can be applied to increase palatability or delay absoφtion. I ectable A parenteral composition suitable for administration by injection is prepared by stirnng 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized. Liposomes can also be used for injectable compositions. Suspension An aqueous suspension is prepared for oral administration so that each 5 ml contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 ml of vanillin. G. METHOD OF TREATMENT The method of treatment can be any suitable method which is effective in the treatment or prevention of the particular virus or viral infection that is being treated or prevented. Treatment can be oral, rectal, topical, parenteral or intravenous administration and the like. The method of applying an effective amount also varies depending on the viral infection being treated and the desired blood level. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of (5 -aryl- 1,2,4- thiadiazol)-3-yl thiourea derivatives or (5-aryl-l,2,4-thiadιzol)-3-yl urea derivatives, formulated with an appropriate carrier, additional viral inhibiting compound or compounds or diluent to facilitate application will be the preferred method of administering the compounds to mammals or warm blooded animals. The following example is illustrative and is not meant to be limiting to the invention. H. Test Methods Prevention Test Unmfected cells were pretreated with the compound for one week, three weeks, four weeks and five weeks respectively by combining the drug with the CEMSS cells. At the end of the culture period, the cells were washed free of the test compound and the cells were used as target cells to titrate a stock solution of HIV virus. Briefly a known virus stock was titrated in each cell line by addition virus to the round bottom microtiter plate at known dilutions (1 :1 through 1:1000) and the amount of virus required to productively infect and kill the CEMSS cells was quantified. Endpoint quantification was performed by XTT assay. XTT Staining of Screening Plates After 6 days (or the experimental period) of incubation at 37°C in a 5% carbon dioxide incubator, the test plates were analyzed by staining with the tetrazolium dye, XTT. XTT-tetrazolium is metabolized by the mitochondrial enzymes of metabolically active cells to a soluble formazan product, allowing the rapid quantitative analysis of the inhibiting of HIV-induced cell killing by an anti-HIV test substance. On day 6 post- infection, plates are removed from the incubator and observed. The use of round bottom microtiter plates allows rapid macroscopic analysis of the active of a given test compound by the evaluation of pellet size. The results of the macroscopic observations were confirmed and enhanced by further microscopic analysis. XTT solutions are prepared daily as a stock of 1 mg/ml in PBS. Phenazine methosulfate (PMS) solution is prepared at 15 mg/ml in PBS and sorted in the dark at 20°C. XTT/PMS stock is prepared immediately before use by diluting the PMS in 1 :100 into PBS and adding 40 ml per ml of XTT solution. Fifty microliters of XTT/PMS is added to each well of the plate and the plate is reincubated for 4 hours at 37°C. Adhesive plate sealers are used in place of the lids and the sealed plate is inverted several times to mix the soluble formazan product. The plated is read spectrophotometrically at 450 nm with a Molecular Devices Vmax plate reader. Percent cell reduction, percent cell viability, IC 25 50 & 95 can then be calculated. Example 1 CEMSS cells were treated in vitro with (5-phenyl-l,2,4-thiadiazol)-3-yl thiourea for from 1 to 5 weeks. The cells were then challenged with HIV 1 after treatment for 1 week, 3 weeks, 4 weeks and 5 weeks respectively. The concentrations of HIV required to infect the cells was measured in μL/well. Cell Treatment Week 1 Week 3 Week 4 Week 5 Control -CEMSS 0.5 μL 0.25 μL 0.3 μL 0.25 μL (5-phenyl-l,2,4-thiadiazol)-3-yl 0.13 μL > 0.13 μL >2 μL >25 μL thiourea 7 μg/ml (5-phenyl-l,2,4-thiadiazol)-3-yl 0.25 μL > 0.25 μL >2 μL >25 μL thiourea 15 μg/ml (5-phenyl-l,2,4-thiadiazol)-3-yl 0.25 μL > 0.25 μL >2 μL >25 μL thiourea 30 μg/ml After 4 weeks of treatment with (5-phenyl-l,2,4-fhiadiazol)-3-yl thiourea there was a 100 fold increase in the ability to protect cells from infection with HIV at all dose levels.

Claims: What is claimed is. 1. The use of a pharmaceutical composition m a use of preventing HIV and retroviral infections wherein said composition comprises a therapeutically effective amount of a (5-aryl- l,2,4-thιadιazol)-3-yl thiourea denvative or (5-aryl- l,2,4-thιadιzol)-3-yl urea denvative having the formula: wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 1-4, R, is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro. oxychloro, alkoxy having the formula -0(CH 2 ) v CH 3 wherein y is from 1 to 6, or the pharmaceutically acceptable acid addition salt or prodrugs thereof. 2. A use according to claim 1 wherein said composition comprises a therapeutically effective amount of a pharmaceutical composition compnsmg (5-phenyl-l,2,4-thιadιazol)-3-yl thiourea or the pharmaceutical addition salt thereof or the prodrugs thereof. 3. A use according to claim 1 or 2 wherein said composition an amount sufficient to deliver from mg/kg body weight to 10000 mg/kg body weight of said (5-aryl- l,2,4-thιadιazol)-3-yl thiourea denvative. 4. A use according to claim 1,2 or 3 wherein said composition comprises an adjunct therapy with said (5-aryl- l,2,4-thιadιazol)-3-yl thiourea denvative or (5-aryl- l,2,4-thιadιzol)-3-yl urea denvative 5. A use according to claim 4 wherein said adjunct therapy comprises a member selected from the group consisting of AZT, TC-3 and protease inhibitors. 6. A use according to Claim 1,2,3,4, or 5 wherein said (5-aryl- l,2,4-thιadιazol)-3-yl thiourea is in a solid form and wherein said solid form mcludes a earner selected from the group consisting of lactose, sucrose, gelatin and agar. 7. A use according to Claim 1,2,3,4 or 5 wherein said (5-aryl- l,2,4-thιadιazol)-3-yl thiourea is m a liquid form and wherein said liquid dosage form is selected from the group consisting of aqueous solutions, alcohol solutions, emulsions, suspensions, liposomes or suspensions reconstituted from non-effervescent and effervescent preparations and suspensions m pharmaceutically acceptable fats or oils. 8. A use according to claims 1,2,3,4,5,6 or 7 wherein said composition compnses (5-phenyl- l,2,4-thιadιazol)-3-yl thiourea.

Inventors: CAMDEN JAMES BERGER, CAMDEN, JAMES, BERGER
Applicants: PROCTER & GAMBLE, THE PROCTER & GAMBLE COMPANY
Application year: 2000
Main classification: A61K31
IPC codes: A61K9, A61K31, A61K45, A61K47, A61P31, C07D285